Glen Eagle Advisors’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $4.62M | Buy |
21,237
+122
| +0.6% | +$27.1K | 0.65% | 32 |
|
|
2025
Q4 | $4.82M | Buy |
21,115
+2,173
| +11% | +$495K | 0.66% | 33 |
|
|
2025
Q3 | $4.39M | Sell |
18,942
-125
| -0.7% | -$25.5K | 0.61% | 34 |
|
|
2025
Q2 | $3.54M | Sell |
19,067
-211
| -1% | -$39.2K | 0.54% | 35 |
|
|
2025
Q1 | $4.04M | Buy |
19,278
+171
| +0.9% | +$33.2K | 0.67% | 32 |
|
|
2024
Q4 | $3.4M | Buy |
19,107
+830
| +5% | +$153K | 0.56% | 36 |
|
|
2024
Q3 | $3.61M | Buy |
18,277
+470
| +3% | +$87.7K | 0.61% | 35 |
|
|
2024
Q2 | $3.05M | Buy |
17,807
+716
| +4% | +$119K | 0.56% | 38 |
|
|
2024
Q1 | $3.11M | Sell |
17,091
-455
| -3% | -$78.4K | 0.59% | 40 |
|
|
2023
Q4 | $2.72M | Sell |
17,546
-165
| -0.9% | -$24.1K | 0.57% | 41 |
|
|
2023
Q3 | $2.64M | Buy |
17,711
+440
| +3% | +$64.6K | 0.61% | 37 |
|
|
2023
Q2 | $2.33M | Buy |
17,271
+762
| +5% | +$112K | 0.54% | 43 |
|
|
2023
Q1 | $2.63M | Buy |
16,509
+568
| +4% | +$86.8K | 0.66% | 37 |
|
|
2022
Q4 | $2.58M | Sell |
15,941
-38
| -0.2% | -$5.83K | 0.7% | 37 |
|
|
2022
Q3 | $2.14M | Buy |
15,979
+168
| +1% | +$24.1K | 0.62% | 38 |
|
|
2022
Q2 | $2.42M | Buy |
15,811
+204
| +1% | +$31.2K | 0.66% | 39 |
|
|
2022
Q1 | $2.53M | Buy |
15,607
+295
| +2% | +$42.9K | 0.66% | 37 |
|
|
2021
Q4 | $2.07M | Sell |
15,312
-245
| -2% | -$28.9K | 0.54% | 43 |
|
|
2021
Q3 | $1.68M | Buy |
15,557
+1,959
| +14% | +$224K | 0.49% | 51 |
|
|
2021
Q2 | $1.53M | Buy |
13,598
+479
| +4% | +$53.9K | 0.48% | 51 |
|
|
2021
Q1 | $1.41M | Buy |
13,119
+974
| +8% | +$104K | 0.49% | 48 |
|
|
2020
Q4 | $1.3M | Sell |
12,145
-94
| -0.8% | -$9.03K | 0.51% | 45 |
|
|
2020
Q3 | $1.07M | Buy |
12,239
+1,104
| +10% | +$104K | 0.48% | 47 |
|
|
2020
Q2 | $1.09M | Buy |
11,135
+3,281
| +42% | +$289K | 0.56% | 43 |
|
|
2020
Q1 | $598K | Buy |
7,854
+3,763
| +92% | +$321K | 0.42% | 54 |
|
|
2019
Q4 | $362K | Buy |
4,091
+352
| +9% | +$29.2K | 0.19% | 107 |
|
|
2019
Q3 | $283K | Sell |
3,739
-131
| -3% | -$8.98K | 0.19% | 112 |
|
|
2019
Q2 | $281K | Buy |
3,870
+353
| +10% | +$27.7K | 0.19% | 111 |
|
|
2019
Q1 | $283K | Buy |
3,517
+356
| +11% | +$29.1K | 0.21% | 105 |
|
|
2018
Q4 | $291K | Buy |
3,161
+30
| +1% | +$2.64K | 0.25% | 90 |
|
|
2018
Q3 | $296K | Sell |
3,131
-170
| -5% | -$16.1K | 0.21% | 107 |
|
|
2018
Q2 | $306K | Buy |
3,301
+241
| +8% | +$23.5K | 0.24% | 92 |
|
|
2018
Q1 | $290K | Buy |
3,060
+386
| +14% | +$42.4K | 0.24% | 99 |
|
|
2017
Q4 | $259K | Sell |
2,674
-174
| -6% | -$16.4K | 0.22% | 103 |
|
|
2017
Q3 | $253K | Sell |
2,848
-24
| -0.8% | -$1.83K | 0.24% | 104 |
|
|
2017
Q2 | $208K | Buy |
2,872
+2
| +0.1% | +$134 | 0.17% | 122 |
|
|
2017
Q1 | $187K | Buy |
2,870
+2
| +0.1% | +$126 | 0.16% | 126 |
|
|
2016
Q4 | $180K | Buy |
+2,868
| New | +$175K | 0.16% | 127 |
|
Other funds holding ABBV
VCM
VPM
Glen Eagle Advisors's ABBV Position: Q1 2026 in Review
Glen Eagle Advisors increased its AbbVie (ABBV) stake by 0.58% in Q1 2026, buying an estimated $27.1K and bringing the position to 21,237 shares worth $4.62M. The position accounts for 0.65% of the portfolio, ranked #32.
Glen Eagle Advisors first reported a position in ABBV in Q4 2016 and has held it in 38 quarters since. The position peaked at $4.82M in Q4 2025. 4,076 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.
- Glen Eagle Advisors held 21,237 shares of AbbVie worth $4.62M as of Q1 2026.
- Glen Eagle Advisors bought 122 AbbVie shares in Q1 2026, an estimated $27.1K.
- AbbVie made up 0.65% of Glen Eagle Advisors's portfolio in Q1 2026, its #32 holding.
- Glen Eagle Advisors first reported a position in AbbVie in Q4 2016 and has held it in 38 quarters since.
- Glen Eagle Advisors's AbbVie position peaked at $4.82M in Q4 2025.
- 4,076 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.
Based on Glen Eagle Advisors's 13F filing for Q1 2026, filed 15 May 2026.